BioCryst Pharmaceuticals, Inc. (BCRX) vs Danaher Corporation (DHR)
The same free fields, in the same order, for both companies, so a figure on one line can be read straight across.
This page states measurements and nothing else. It does not rank the two companies, name one of them, or draw a conclusion from the figures.
Data as of Oct 27, 2026, for both companies.
The figures, field by field
A dash means the snapshot carries no figure for that company on that line. A line is dropped only when neither company has it, so a dash beside a figure is a fact about coverage, not about either company.
| BCRX | DHR | |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic | Diagnostics & Research |
| Size band | MID | LARGE |
| Listing | Nasdaq GS | NYSE |
| Country | United States | United States |
| Theme | rare-disease | life-science-tools |
| Price and returns | ||
| Last close | $7.88 | $232.97 |
| Return · 1 week | −2.35% | +3.81% |
| Return · 1 month | −6.97% | +2.66% |
| Return · 3 months | −19.10% | +17.04% |
| Return · year to date | +5.07% | +1.33% |
| Return · 1 year | +7.80% | +5.78% |
| Distance from the 52-week highThe last close measured against the highest close of the past 52 weeks. | −29.77% | −4.05% |
| 52-week high | $11.22 | $242.80 |
| 52-week low | $6.23 | $160.93 |
| Size and turnover | ||
| Market value · USDConverted to US dollars, so two companies listed in different currencies sit under one heading. | $2.01B | $163.77B |
| Turnover · median day, USDThe median value traded in a session over the past 50 sessions. | $31.35M | $834.36M |
| Employees | 435 | 58,000 |
| Valuation | ||
| Price to earnings · trailing | n/a (negative earnings) | 39.18× |
| Price to earnings · forward | 9.10× | 23.64× |
| Price to sales | 2.32× | 6.15× |
| Price to book | n/a (negative book value) | 2.94× |
| Enterprise value to EBITDA | 6.08× | 22.06× |
| Enterprise value to revenue | 2.80× | 7.05× |
| PEG ratio | 9.39 | 1.29 |
| Earnings per share · trailing | -1.40 | 5.61 |
| Profitability | ||
| Gross margin | 97.78% | 58.51% |
| Operating margin | 45.12% | 19.78% |
| Profit margin | −40.90% | 15.89% |
| Return on equity | — | 7.61% |
| Return on assets | 52.86% | 3.95% |
| Growth | ||
| Revenue growth | +33.60% | +5.50% |
| Earnings growth | +1400.00% | +59.70% |
| Balance sheet and payout | ||
| Debt / equity (%) | — | 52.97 |
| Current ratio | 2.32 | 1.65 |
| Dividend yield | 0.00% | 0.74% |
| Payout ratio | 0.00% | 25.67% |
| Trend and volatility | ||
| RSI · 14 | 42.16 | 62.01 |
| ADX · 14 | 19.52 | 31.94 |
| 50-day average | $8.75 | $216.74 |
| 200-day average | $8.72 | $201.19 |
| Average true range · share of priceAverage true range over 14 sessions, stated as a share of the last close, so it can be read across two share prices. | 3.92% | 2.78% |
The full BCRX analysis
Everything this table leaves out for BioCryst Pharmaceuticals, Inc.: the plain-language summary and key points, the accumulation read, signal history, full fundamentals, market context, and the case each side of the BCRX argument makes.
$9.90 per stock, one time, 30 days of access.
Open the full BCRX analysisThe full DHR analysis
Everything this table leaves out for Danaher Corporation: the plain-language summary and key points, the accumulation read, signal history, full fundamentals, market context, and the case each side of the DHR argument makes.
$9.90 per stock, one time, 30 days of access.
Open the full DHR analysis